# Inocras

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inocras

- Industry: Software
- Headquarters: San Diego, US
- Website: http://www.genomeinsight.net
- Total disclosed funding: $6.2M
- Latest round: Series A (Nov 27, 2020)
- Investors on record: 3

## About

Inocras Inc. is a US-based company focused on advanced genomic testing solutions, offering comprehensive insights into genetics for patients and healthcare providers through innovative sequencing technologies.Founded in 2020, Inocras Inc. operates from San Diego, US, specializing in genomic tests for cancer and rare diseases. The company has completed three funding rounds, with the latest being a Series A round raising KRW 6500.000 mn on December 5, 2024, involving investors such as DSC Investment, Paratus Investment, and Schmidt. The leadership includes founders Jeong-seok Lee and Young-seok Ju, with Je-hee Suh serving as CEO.Inocras specializes in whole genome sequencing tests designed to provide comprehensive genetic insights for patients, healthcare providers, and researchers. Their core offerings include CancerVision, which analyzes solid tumors, and RareVision, aiding in diagnosing over 5,000 rare diseases. These tests utilize advanced sequencing technologies and AI to generate actionable insights, enabling informed clinical decision-making. The company primarily serves clients in the US and select international markets.Inocras generates revenue through its genomic testing services, including CancerVision and RareVision. It operates on a direct-to-consumer model while partnering with healthcare providers and research institutions. Revenue comes from client orders for genomic tests, typically referred by healthcare professionals, with a turnaround time of two weeks for results. The pricing structure reflects the advanced technology and comprehensive analysis provided by their tests.In December 2024, Inocras Inc. secured venture funding from investors including Big Move Ventures and Samsung Venture Investment, aimed at enhancing its growth strategy. The company is planning to introduce new products to expand its genomic test offerings by mid-2025. Additionally, Inocras is targeting expansion into new international markets with advanced healthcare infrastructure, intending to leverage its recent funding to support these initiatives.

## Funding rounds

- Series A, Nov 27, 2020, $5.9M — DSC Investment, Paratus Investment, Schmidt
- Seed, Feb 1, 2020, $0.3M — DSC Investment, Schmidt

## Investors

- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Seed, Series A
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Seed, Series A
- Paratus Investment (https://capitalatlas.ai/funds/paratus-investment) — Series A